# **Immunoglobulin A Nephropathy (IgAN)/Immunoglobulin A Vasculitis (IgAV)**
## **Overview**
 * IgAN
      1. Glomerular Disease w/co-dominant IgA Glomerular staining
      2. Three types: Primary, Secondary, and Systemic forms (IgA Vasculitis)
      3. Most commen pattern of primary glomerular disease world wide
      4. Most prevalent in people of East Asian ancestry followed by Caucasians
      5. IgA deposistion can be found in MCD: if IgA found on kidney biopsy but otherwise consistent w/MCD, patient should be treated with therapy directed towards MCD
      6. Mest-C Score: Risk tool/score provide earlier risk predicition in IgAN
         - M --> Mesangial hypercellularity
         - E --> Endocapillary hypercellularity
         - S --> Segmental Sclerosis
         - T --> Interstitial fibrosis/Tubular atrophy
         - C --> Crescents 
 * IgA Vasculitis
      1. IgA autoantibodies deposition in the vessels
      2. Children < 16 years of age, often self limitting
      3. Glomerular disease 30% children, 60% Adults
      4. Worse GN in children, worse outcomes in Adults
      5. Adults typicaly more severe and relapsing disease
## **Pathophysiology**
 * IgAN
      1. GN with co-dominant IgA glomerular staining with IgA deposistion in the Mesangial +/- Capillary
      2. IgG typically also presented along with C3
      3. 4 HIT Model
         - Production of poorly glycosylated IgA1 (Gd-Ig-A1)
         - Production Anti-Gd-IgA1 autoantibodies (anti-Gd-IgA1 autoantibodies)
         - Formation of Glomerular deposition of Immuncomplexes
         - Deposition of circulating immunce complexes --> Mesangial, Podocyte, Endothelial inducingc cytokine release, compliment activation, and inflammation causing injury
    4. Acute Lesion
         - Mesangial Hypercellularity
         - Endocapillary Hypercellularity
         - Crescent
         - FSGS and podocytopathy
     5. Chronic lesions: corelate with outcome
        - IFTA
        - FSGS
        - Global Sclerosis
        - Arteriosclerosis
 * Mest-C
      1. T score: Most Consistent predictor of Renal Survival
      2. M1, S1, T1/2: Worse outcomes, Regardless of Immunosupression status
      3. E1 and C1: Poor out comes in patient not treated w/Immunosupression
      4. C2: Predicitive of poor outcomes regardless of Immunosupression (not synonymous w/RPGN)
      5. S1 w/podocytopathy: heavier proteinuria and Rapid eGFR loss --> Better response to steroids 
 * IgAV
      1. Systemic vasculities IgA1-dominant deposits
      2. IgA autoantibodies desposition in the small vessels affecting: skin, joints, intestines, and kidney (rarely affects lungs and CNS)
## **Clinical Presentation**
 * Hematuria
 * Proteinuria: Rarely > 3.5g/d
 * Edema
 * HTN
## **Diseases Associated with IgAN/IgAV**
  * Diseases
    1. Cirrhosis
    2. Portal HTN
    3. Inflammatory Bowel Disease
    4. Celiac
    5. Dermatits Herpetiformis
    6. Psoriasis
  * Infections
    1. HIV
    2. Hepatitis 
    3. TB
    4. Brucellosis
    5. Lerosy 
## **Treatment**
### IgAN
```mermaid
---
config:
  theme: redux
---
flowchart TD
    A(["IgA Dominant on Bx"]) --> n1["**Consider Secondary Causes**
    • IgA Vasculitis
    • Viral causes
    • IBD
    • Autoimmune Disease
    • Cirrhosis 
    • IgA dominant Infection related GN"]
    n1 -- Secondary cause found --> n2["Treat primary Disease State"]
    n1 -- Secondary cause not found --> n3(["Ideopathic IgAN"])
    n3 --> n4["• MEST-C Score
    • Risk Prediction tool"]
    n4 --> n5["• Report in Disease registry if available
    • Give patient resources for patient advocacy groups
    • Consider enrollment in Trials"] & n6["Consider treatment for Patients at risk of progressive kidney function loss w/supportive therapy and Targeted therapy"] & n9(["IgAN w/RPGN"])
    n6 -- Targeted Therapy --> n7["• Nefecon/Glucocorticoids
    • MMF/Hydroxychloroquine
    • Tonsillectomy"]
    n6 -- Supportive Therapy --> n8["• Life style changes
    • RASi or DEARA/Sparsentan
    • SGLT2i"]
    n9 --> n10["Offer Treatement with cyclophosphamide and systemic steroids in accordance ANCA-associated Treatement"]
    n7 --> n11["• Nefecon: Recommend 9 month course
    • Methylprednisonolone: 0.4 mg/kg/day (max 32mg/day) for 2 months
 • Taper Methylpred by 4 mg/day for 6-9months
• Can sub Methylpred for prednison: Methylprednisone 1mg = Prednisone 1.25mg
• PJP ppx"] & n12@{ label: "• MMF: can be used as glucocorticoid sparring agent in Chinese patients only\n    • Hydroxychloroquine: For patients at high risk of progression inspite of supportive care in Chinese patients only\n    • Tonsillectomy: For Japanese patient's (not studied in any other group)" }
    n1@{ shape: rounded}
    n4@{ shape: rounded}
    n5@{ shape: rounded}
    n6@{ shape: rounded}
    n7@{ shape: rounded}
    n8@{ shape: rect}
    n12@{ shape: rect}
    style A fill:#C8E6C9,color:#000000
    style n1 fill:#FFF9C4,text-align:left,white-space:nowrap
    style n2 fill:#FFE0B2,text-align:left
    style n3 fill:#C8E6C9,text-align:left
    style n4 fill:#FFF9C4,text-align:left
    style n5 fill:#FFF9C4,text-align:left
    style n6 fill:#FFF9C4,text-align:left
    style n9 fill:#C8E6C9,text-align:left
    style n7 fill:#FFF9C4,text-align:left,white-space:nowrap
    style n8 fill:#FFE0B2,text-align:left,white-space:nowrap
    style n10 fill:#FFE0B2,text-align:left
    style n11 fill:#FFE0B2,text-align:left,white-space:nowrap
    style n12 fill:#FFE0B2,text-align:left,white-space:nowrap
```

  * [IgAN prediction tool at biopsy - Adult](https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool-at-biopsy-adults)
  * [IgAN prediction tool post-biopsy - Adult](https://qxmd.com/calculate/calculator_839/international-igan-prediction-tool-post-biopsy-adults)
### Medicaions approved recently by FDA for IgAN
  * Nefecon (TRF-Budesonide, 2021)
  * Sparsentan (2023)
    1. Should avoid use with ACEi/ARB due to DEARA
    2. REMS: Requires Monthly liver testing for first 12month, then every 3 months thereafter 
  * Iptocopan (2024)
  * Atrasentan (2025)
    1. Endothelial Antagonist only an be used with ACEi/ARB
    2. No REMS
### New therapies currently being studied 
  * Target: APRIL
    1. Sibeprenlimab (Trial: VISIONARY)
    2. Zigakibart (Trial: BEYOND)
  * Target: APRIL/BAFF
    1. Telitacicept (Trial: NCT05799287)
    2. Povetacicept (Trial: APPLAUSE-IgAN)
  * Target: Alternative pathway, factor B
    1. Sefaxersen (Trial: IMAGINATION)
  * Target: Terminal point in Complement pathway, C5
    1. Ravulizumab (Trial: I CAN)
### IgAV
  * No proven therapy at this time
  * Age appropiate Malignancy Screening
  * Consider Glucocorticoid therapy
  * Supportive Therapy: RASi, Life style changes (diet, exercise, < 2g salt per day), SGLT2i
  * Recommend enrolling in clinical trials
  * RPGN: Offer Treatement with cyclophosphamide and systemic steroids in accordance ANCA-associated Treatement
## **Sources**
 * [KDIGO Guidlines IgAN 2025](https://kdigo.org/wp-content/uploads/2024/08/KDIGO-2025-IgAN-IgAV-Guideline.pdf)
 * [Proteinuria Trajectory and Disease Progression in Children and Adults w/IgA Nephropathy/Vasculitis](https://renal.videomed.live/videos/069bdab11e1ce0c48c/2025-07-17-10-20-pathology-of-ig-a-nephropathy-and-ig-a-vasculitis-m-barry-stokes-md)
 * [Indications for Corticosteroids in IgA Nephropathy](https://pubmed.ncbi.nlm.nih.gov/35108391/)
 * [Oxford Classification of IgA Nephropathy](https://pubmed.ncbi.nlm.nih.gov/19571790/)
 * [Uptodate IgA nephropathology](https://www-uptodate-com.ezproxy.ttuhsc.edu/contents/iga-nephropathy-pathogenesis?search=drug%20associated%20iga%20nephropathy&source=search_result&selectedTitle=5~103&usage_type=default&display_rank=5)
 * [Atrasentan in patients w/IgAN; ALIGN](https://www.nejm.org/doi/full/10.1056/NEJMoa2409415)
 * [Iptacopan in IgAN; APPLAUSE](https://www.nejm.org/doi/full/10.1056/NEJMoa2410316
 * [Sibeprenlimab in IgAN; ENVISION](https://pubmed.ncbi.nlm.nih.gov/37916620/)
 * [Sparsentan in IgAN; PROTECT](https://pubmed.ncbi.nlm.nih.gov/37931634/)
 * [NEFECON in IgA; NEfIGArd](https://pubmed.ncbi.nlm.nih.gov/39724565/)
 * [Efficacy and safety of Nefecon](https://www.sciencedirect.com/science/article/abs/pii/S0140673623015544)
 * [Steroids in IgA; TESTING](https://pubmed.ncbi.nlm.nih.gov/34731857/)
 * [Intensive supportive care plus immunosuprerssion in IgAN; STOP-IgAN](https://www.nejm.org/doi/full/10.1056/NEJMoa1415463)
 * [Henoch-Schonlein purpura in adults](https://www.scopus.com/pages/publications/0036232277)
 * [Sparsentanin patietn with IgA, interim analysis](https://www.sciencedirect.com/science/article/abs/pii/S014067362300569X)
 * [Targeting Endothelin A receptor in IgAN](https://www.sciencedirect.com/science/article/pii/S246802492301402X)
 * [Empagliflozin in CKD](https://scholar.google.com/scholar_lookup?title=Empagliflozin%20in%20patients%20with%20chronic%20kidney%20disease&author=The%20EMPA-KIDNEY%20Collaborative%20Group&publication_year=2023&pages=117-127)
 * [ACEi in children and young people w/IgAN](https://www.scopus.com/pages/publications/34249897747)
 * [Risk-Predicition tool evaluation](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2730331)
 * [MMF in IgA](https://www.sciencedirect.com/science/article/pii/S008525381549917X)
 * [MMF w/prednisone in IgA](https://www.sciencedirect.com/science/article/abs/pii/S0272638617300082)
 * [Prednisone and ACEi vs ACE alone in IgAN](https://www.sciencedirect.com/science/article/abs/pii/S0272638608012304)
 * [10 year follow up in IgA supportive care vs supportive care and immunosupression](https://www.sciencedirect.com/science/article/pii/S0085253820305494)
 * [Methylprednisolone on decline in kidney function or failure in IgAN](https://jamanetwork.com/journals/jama/fullarticle/2792252)
 * [Key pathogenic biomarkers in IgAN with Nefecon](https://www.sciencedirect.com/science/article/pii/S0085253823007780)
---
*Last updated: 9/2025 by Ashley Kinder, D.O.*
*Next review: 9/2026*
